JOURNAL ARTICLE
Simultaneous echocardiography and myocardial perfusion single photon emission computed tomography associated with dobutamine stress to predict long-term cardiac mortality in normotensive and hypertensive patients.
Journal of Hypertension 2005 July
BACKGROUND: Echocardiography and myocardial scintigraphy associated with dobutamine stress are used for assessing risk in coronary artery disease. We compared the accuracy of the two modalities applied simultaneously for predicting long-term cardiac mortality in normotensive and hypertensive patients.
METHODS: Three hundred and fifty-one consecutive patients underwent dobutamine stress with simultaneous echocardiography and Tc-sestamibi single photon emission computed tomography (SPECT). Fifty patients underwent early (<60 days) revascularization and were excluded; the analysis is based on 301 patients (131 hypertensives and 170 normotensives).
RESULTS: The prevalence of additional risk factors, heart failure, prior myocardial infarction and prior revascularization was similar in the two groups of patients. An abnormal stress echocardiogram was detected in 101 (59%) normotensives and 80 (61%) hypertensives (NS), while 113 (66%) normotensives and 83 (63%) hypertensives (NS) showed abnormal myocardial perfusion. The agreement was 81% (kappa = 0.59) in hypertensives and 82% (kappa = 0.62) in normotensives. During 7.3 +/- 2.8 years of follow-up, 17 (13%) hypertensives and 26 (15%) normotensives died from cardiac causes (P = 0.62). In normotensives, the annual mortality rate was 0.8 for normal echo and 1.3 for normal scan, 2.8 for abnormal echo and 2.6 for abnormal scan. In hypertensives, it was 0.5 for normal echo, 0% for normal scan, 2.6 for abnormal echo and 2.8 for abnormal scan. Each test was associated with higher survival in the case of negative compared to positive results in both normotensive and hypertensive patients (log-rank chi-square 16.4, P < 0.001).
CONCLUSIONS: Dobutamine stress echocardiography and SPECT are equally effective in predicting long-term cardiac death in both normotensive and hypertensive patients.
METHODS: Three hundred and fifty-one consecutive patients underwent dobutamine stress with simultaneous echocardiography and Tc-sestamibi single photon emission computed tomography (SPECT). Fifty patients underwent early (<60 days) revascularization and were excluded; the analysis is based on 301 patients (131 hypertensives and 170 normotensives).
RESULTS: The prevalence of additional risk factors, heart failure, prior myocardial infarction and prior revascularization was similar in the two groups of patients. An abnormal stress echocardiogram was detected in 101 (59%) normotensives and 80 (61%) hypertensives (NS), while 113 (66%) normotensives and 83 (63%) hypertensives (NS) showed abnormal myocardial perfusion. The agreement was 81% (kappa = 0.59) in hypertensives and 82% (kappa = 0.62) in normotensives. During 7.3 +/- 2.8 years of follow-up, 17 (13%) hypertensives and 26 (15%) normotensives died from cardiac causes (P = 0.62). In normotensives, the annual mortality rate was 0.8 for normal echo and 1.3 for normal scan, 2.8 for abnormal echo and 2.6 for abnormal scan. In hypertensives, it was 0.5 for normal echo, 0% for normal scan, 2.6 for abnormal echo and 2.8 for abnormal scan. Each test was associated with higher survival in the case of negative compared to positive results in both normotensive and hypertensive patients (log-rank chi-square 16.4, P < 0.001).
CONCLUSIONS: Dobutamine stress echocardiography and SPECT are equally effective in predicting long-term cardiac death in both normotensive and hypertensive patients.
Full text links
Trending Papers
Management of Latent Tuberculosis Infection.JAMA 2023 January 20
Chronic Kidney Disease, Urinary Tract Infections and Antibiotic Nephrotoxicity: Are There Any Relationships?Medicina 2022 December 28
How I Treat Multiple myeloma in the geriatric patient.Blood 2023 January 25
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app